Materiality Navigator — Healthcare Providers, Services and Technology

Environment
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Safe segregation, handling, storage, transport and treatment of hazardous and infectious healthcare waste generated by clinical care, diagnostics, laboratories, pharmacy and facilities operations.

How it shows up in this industry

Hospitals, laboratories, theatres, pharmacies, blood banks, dialysis units, maternity services, sterilisation units and outpatient centres generate sharps, infectious materials, cytotoxic waste, anatomical waste, contaminated single-use plastics and pharmaceutical returns. Segregated collection, regulated returns or destruction, specialist treatment, incineration and autoclaving are critical operational pathways.

Why it may be material

Clinical waste is unavoidable in health care delivery and is cost intensive and highly regulated. Mis-segregation increases incineration volumes and contractor costs, while failures in sharps, cytotoxic or pharmaceutical waste handling can create worker injury claims, contamination liabilities, enforcement action and reputational damage.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach supply-chain workers.
Potential effects may reach affected communities.
Potential effects may reach ecosystems.
Potential effects may reach the atmosphere.
Potential effects may reach soil and groundwater.
Potential effects may reach water bodies.
Affected stakeholder groups identified in the source include Affected communities, Contractors, Employees, Suppliers.
The source places the pathway in Own operations, Downstream, Upstream.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on workers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Supplier workforce, audit, grievance and remediation records
Community engagement, grievance and impact records
Biodiversity, habitat and ecosystem-impact evidence
Emissions, air-quality and atmospheric-impact records linked to the topic
Soil and groundwater monitoring, incident and remediation records
Water withdrawal, discharge, quality and catchment-impact records
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Capital plans, asset adaptation budgets and investment approvals
Revenue, demand, pricing and market-access analysis linked to the topic
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls
Process-map item (assets): Clinical licences, accreditation status, payer contracts, provider networks, care pathways, clinical protocols and patient trust as intangible assets
Process-map item (customers): Pharmaceutical and medical technology companies using provider sites for clinical trials and real-world evidence studies
Process-map item (emerging_pressures): Investor and payer scrutiny of hospital carbon footprints, anaesthetic gases, inhaler choices, energy procurement and waste segregation

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream or upstream pathway.

Affected stakeholders

Affected communities
Contractors
Employees
Suppliers

Users of the information

Board / management
Regulators

Standards to check

ESRS ESRS E5 Resource use and circular economysearch disclosure cards
ESRS ESRS E2 Pollution for hazardous substances may also applysearch disclosure cards
GRI GRI 306 Wastesearch disclosure cards
SASB Waste Management

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Decarbonisation and energy management for hospitals, clinics, laboratories, fleets, clinical gases and material purchased goods used in care delivery.

How it shows up in this industry

Acute hospitals, diagnostic centres, laboratories, sterilisation units, rehabilitation facilities and ambulance fleets use energy-intensive HVAC, boilers, chillers, steam, medical gas systems, backup generators, imaging equipment and transport. Operating theatres and maternity services use volatile anaesthetic agents and nitrous oxide systems, while purchased medicines, consumables, devices, food and linen contribute to upstream emissions.

Why it may be material

Ageing hospital estates face high utility bills, carbon pricing exposure, energy volatility and lender or payer expectations. Anaesthetic gas substitution, nitrous oxide leak reduction, low-carbon heat, fleet changes and efficiency retrofits can reduce operating cost and protect access to financing and public procurement mandates.

Impact pathway

Potential effects may reach the atmosphere.
Potential effects may reach future generations.
Potential effects may reach affected communities.
Potential effects may reach workers.
Affected stakeholder groups identified in the source include Customers / end-users, Employees, Suppliers.
The source places the pathway in Own operations, Upstream, Cross value chain.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on the atmosphere?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Emissions, air-quality and atmospheric-impact records linked to the topic
Long-term scenario, cumulative-impact and intergenerational analysis
Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Funding terms, lender or investor requirements and cost-of-capital analysis
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Acute hospitals with operating theatres, emergency departments, intensive care units, wards, maternity units and isolation rooms
Process-map item (assets): Sterilisation units, pharmacies, blood banks, medical gas manifolds and bulk oxygen tanks
Process-map item (customers): Self-pay patients and medical tourists seeking elective procedures, diagnostics or specialist consultations
Process-map item (customers): Pharmaceutical and medical technology companies using provider sites for clinical trials and real-world evidence studies
Process-map item (customers): Care homes, home health agencies and hospices relying on hospital discharge planning and specialist support

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream pathway.

Affected stakeholders

Customers / end-users
Employees
Suppliers

Users of the information

Board / management
Investors / creditors
Local authorities
Regulators

Standards to check

ESRS ESRS E1 Climate change, including energy and transition planningsearch disclosure cards
GRI GRI 302 Energysearch disclosure cards
GRI GRI 305 Emissionssearch disclosure cards
SASB Energy Management

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Transition of distribution fleets, refrigerated warehousing, energy systems and refrigerants towards lower-emission and more resource-efficient operation while maintaining validated medicine handling requirements.

How it shows up in this industry

Regional distribution centres use lighting, conveyors, robotics, chillers, IT rooms and material-handling equipment, while refrigerated vans, trailers, lorries, emergency couriers and occasional air freight move medicines and devices under strict service-level commitments. Growth in biologics, vaccines and cell therapies increases energy-intensive refrigeration and refrigerant exposure.

Why it may be material

Energy, diesel and refrigerants are recurring OPEX items in 24-hour fulfilment and validated cold-chain logistics. Public buyers, hospitals, manufacturers and investors increasingly require emissions reporting and transition plans, while fleet replacement, charging infrastructure and low-global-warming-potential refrigeration require CAPEX.

Impact pathway

Potential effects may reach the atmosphere.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Potential effects may reach ecosystems.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on the atmosphere?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Emissions, air-quality and atmospheric-impact records linked to the topic
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Biodiversity, habitat and ecosystem-impact evidence
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Revenue, demand, pricing and market-access analysis linked to the topic
Funding terms, lender or investor requirements and cost-of-capital analysis
Insurance coverage, premium, exclusion and claims records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Process-map item (assets): Validated cold rooms, freezers, temperature-controlled trailers and refrigerated vans
Process-map item (assets): Warehouse management, enterprise resource planning, serialisation and track-and-trace platforms
Process-map item (assets): Reverse-logistics facilities for returns, recalls, expired medicines and damaged stock
Process-map item (emerging_pressures): Growth in biologics, GLP-1 medicines, vaccines and cell therapies increasing demand for validated cold-chain capacity
Process-map item (emerging_pressures): More frequent extreme heat, storms and floods disrupting transport lanes and warehouse resilience

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS E1 Climate change; energy and greenhouse gas emissionssearch disclosure cards
GRI GRI 302 Energysearch disclosure cards
GRI GRI 305 Emissionssearch disclosure cards
SASB SASB Health Care Distributors; energy management and fleet emissions-related operational efficiency

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Medicine take-back and end-of-life stewardship covers safe collection, segregation, reverse logistics, recovery and disposal interfaces for unused medicines, inhalers, sharps and patient-returned products after retail, online or delivery pharmacy supply.

How it shows up in this industry

Retail pharmacies are practical collection points for unused prescription medicines, expired products, recalled medicines, inhalers, sharps and related devices generated after dispensing, vaccination and testing. They manage segregation, quarantine, reverse logistics and authorised waste contractors to prevent active pharmaceutical ingredients, inhaler propellants and sharps entering drains, household waste or unsafe handling channels.

Why it may be material

Medicine end-of-life stewardship is increasingly expected by customers, health systems and regulators because incorrect disposal can affect water bodies, ecosystems, households and waste workers. It also influences contractor costs, community trust and eligibility for service contracts requiring take-back or recycling capability.

Impact pathway

Potential effects may reach water bodies.
Potential effects may reach ecosystems.
Potential effects may reach affected communities.
Potential effects may reach consumers.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach supply-chain workers.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Customers / end-users, Suppliers.
The source places the pathway in Downstream, Own operations, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which products, services, customers or end uses create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on water bodies?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Water withdrawal, discharge, quality and catchment-impact records
Biodiversity, habitat and ecosystem-impact evidence
Community engagement, grievance and impact records
Consumer outcome, complaint and product-impact records
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Supplier workforce, audit, grievance and remediation records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): Delivery vans, courier contracts and last-mile delivery infrastructure for home medicines supply
Process-map item (customers): Walk-in retail customers buying prescription medicines, over-the-counter medicines, health and beauty products and medical devices
Process-map item (customers): Carers, care homes and assisted-living facilities requiring monitored dosage systems and medicines administration records
Process-map item (customers): Public and private health insurers, pharmacy benefit managers and national health services reimbursing dispensed medicines

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Business partners
Customers / end-users
Suppliers

Users of the information

Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS E2 pollutionsearch disclosure cards
ESRS ESRS E5 resource use and circular economysearch disclosure cards
GRI GRI waste disclosures and water or effluents-related considerations where residues affect water bodiessearch disclosure cards
SASB SASB Drug Retailers product stewardship, waste management and medicine take-back where sector-specific metrics apply

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Safe, documented management of returned, expired, damaged, recalled, cytotoxic and controlled pharmaceuticals, including authorised destruction and prevention of residues entering water, soil or unauthorised channels.

How it shows up in this industry

Reverse-logistics facilities process saleable returns, recalls, expired stock, damaged goods, sharps containers and products requiring destruction certificates. Waste handlers and distribution staff may handle broken vials, cytotoxic medicines, disinfectants, aerosols, medical gas cylinders, controlled products and pharmaceutical residues.

Why it may be material

Health care distributors are a key control point between pharmacies, hospitals, manufacturers and authorised destruction providers. Poor segregation, spill control or documentation can release pharmaceutical residues and hazardous active ingredients, undermine recall effectiveness and trigger hazardous waste or licence concerns.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Potential effects may reach ecosystems.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Contractors, Customers / end-users, Employees, Suppliers.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on workers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Biodiversity, habitat and ecosystem-impact evidence
Community engagement, grievance and impact records
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Revenue, demand, pricing and market-access analysis linked to the topic
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Specialty pharmaceutical hubs for biologics, cell and gene therapy kits, vaccines and oncology products
Process-map item (assets): Reverse-logistics facilities for returns, recalls, expired medicines and damaged stock
Process-map item (customers): Specialty pharmacies and home delivery medicine providers
Process-map item (emerging_pressures): Expansion of pharmaceutical serialisation, electronic product tracing and interoperable verification requirements

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Business partners
Contractors
Customers / end-users
Employees
Suppliers

Users of the information

Regulators

Standards to check

ESRS ESRS E2 Pollutionsearch disclosure cards
ESRS ESRS E5 Resource use and circular economy; waste and hazardous substancessearch disclosure cards
GRI GRI 306 Wastesearch disclosure cards
GRI GRI 403 Occupational Health and Safety where handling exposure is materialsearch disclosure cards
SASB SASB Health Care Distributors; product safety, recalls and waste-related operational controls

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Industry baseline
Moderate industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Resilience of temperature-controlled distribution assets, power systems and medicine supply routes to physical climate hazards that can disrupt operations, compromise product quality or delay patient access.

How it shows up in this industry

Large high-bay warehouses, regional depots and specialty hubs depend on validated cold rooms, freezers, temperature-controlled trailers, refrigerated vans, IT rooms and back-up power. Severe heat, storms and floods can disrupt transport lanes, cause temperature excursions and impair emergency replenishment for operating theatres, intensive care units, vaccines and shortage medicines.

Why it may be material

Climate hazards increasingly interact with patient access and product integrity. A flooded depot, heatwave-induced refrigeration failure or blocked route can create spoilage, insurance claims, emergency transport costs, missed delivery commitments and public health disruption.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach workers.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What scientific evidence or consensus could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Workforce, health and safety, engagement and grievance records
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Capital plans, asset adaptation budgets and investment approvals
Operating-cost records and budgets linked to the topic
Insurance coverage, premium, exclusion and claims records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Validated cold rooms, freezers, temperature-controlled trailers and refrigerated vans
Process-map item (assets): Warehouse management, enterprise resource planning, serialisation and track-and-trace platforms
Process-map item (assets): Reverse-logistics facilities for returns, recalls, expired medicines and damaged stock
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
Regulators

Standards to check

ESRS ESRS E1 Climate change; physical climate risks and adaptationsearch disclosure cards
GRI GRI 201 Financial implications and other risks and opportunities due to climate changesearch disclosure cards
GRI GRI 416 where product integrity is affectedsearch disclosure cards
SASB SASB Health Care Distributors; business continuity, supply-chain integrity or product safety proxies

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Clinical, sharps and retail packaging waste covers environmental and worker impacts from operational waste streams generated by pharmacy dispensing, testing, vaccination, retail packaging and central-fill activities.

How it shows up in this industry

Drug retailers generate sharps waste, clinical waste, contaminated consumables, confidential paper waste, cardboard, plastic film, paper bags, blister packs, vials and general retail packaging through dispensing, vaccination, testing, minor-ailment services, stock rooms and central-fill hubs. Regulated clinical waste transport and treatment arrangements create important contractor interfaces.

Why it may be material

Expanding in-store clinical services increase sharps and clinical waste while high-volume dispensing creates packaging and confidential paper flows. Poor segregation can contaminate recyclable streams, increase incineration, expose workers and waste handlers to injury, and create regulatory or contractor liability.

Impact pathway

Potential effects may reach ecosystems.
Potential effects may reach water bodies.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach supply-chain workers.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Contractors, Employees, Suppliers.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on ecosystems?
What is the scale, scope, likelihood and remediability of effects on water bodies?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Biodiversity, habitat and ecosystem-impact evidence
Water withdrawal, discharge, quality and catchment-impact records
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Supplier workforce, audit, grievance and remediation records
Community engagement, grievance and impact records
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Vaccination, testing and minor-ailment service facilities within retail premises
Process-map item (assets): Brand reputation, pharmacy licences, payer network contracts and supplier trading agreements

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Business partners
Contractors
Employees
Suppliers

Users of the information

Regulators

Standards to check

ESRS ESRS E5 resource use and circular economysearch disclosure cards
ESRS ESRS E2 pollution for hazardous or clinical waste aspectssearch disclosure cards
GRI GRI waste disclosuressearch disclosure cards
SASB SASB Drug Retailers waste management and packaging impacts where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Waste, material persistence and circularity challenges from the packaging systems used to protect medicines, vaccines, diagnostics and devices during pharmaceutical distribution.

How it shows up in this industry

Medicine distributors use corrugated cartons, plastic totes, shrink wrap, tamper-evident seals, desiccants, insulated shippers, gel packs, dry ice packaging and phase-change materials to meet Good Distribution Practice and cold-chain validation. Emerging restrictions on PFAS, PVC, expanded polystyrene and other packaging materials are changing pharmaceutical logistics design.

Why it may be material

Growth in biologics, vaccines and frozen therapies increases single-use cold-chain packaging, while customer waste targets and material restrictions affect procurement, validation and customer acceptance. Substitutions must protect temperature control, tamper evidence, sterility protection and product identification.

Impact pathway

Potential effects may reach ecosystems.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Potential effects may reach downstream users.
Affected stakeholder groups identified in the source include Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Biodiversity, habitat and ecosystem-impact evidence
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Downstream-user outcome, complaint and product-use evidence
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Revenue, demand, pricing and market-access analysis linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Validated cold rooms, freezers, temperature-controlled trailers and refrigerated vans
Process-map item (assets): Warehouse management, enterprise resource planning, serialisation and track-and-trace platforms
Process-map item (customers): Medical device distributors, laboratory suppliers and secondary wholesalers
Process-map item (emerging_pressures): Expansion of pharmaceutical serialisation, electronic product tracing and interoperable verification requirements
Process-map item (emerging_pressures): Growth in biologics, GLP-1 medicines, vaccines and cell therapies increasing demand for validated cold-chain capacity

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
NGOs / civil society
Regulators

Standards to check

ESRS ESRS E5 Resource use and circular economysearch disclosure cards
ESRS ESRS E2 Pollution where substances of concern in materials are relevantsearch disclosure cards
GRI GRI 301 Materialssearch disclosure cards
GRI GRI 306 Wastesearch disclosure cards
SASB SASB Health Care Distributors; waste management or supply chain management aspects where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Management of healthcare water demand and routine wastewater quality, including clinical, laboratory, sterilisation, dialysis, laundry, cooling, catering and cleaning effluent pathways.

How it shows up in this industry

Hospitals, dialysis units, sterilisation services, laundries, laboratories, theatres, catering, cooling towers, cleaning and patient hygiene require reliable water supplies. Wastewater may contain disinfectants, antibiotics, contrast agents, hormones, pathogens and microplastics from clinical activity and single-use products, with significance shaped by local treatment infrastructure and receiving waters.

Why it may be material

Water is essential to safe clinical operations, and effluent can transfer pharmaceuticals, disinfectants, pathogens and microplastics to water bodies. Materiality increases where facilities operate in water-stressed catchments or where dialysis, laundry, oncology, imaging, laboratory or sterilisation volumes are high.

Impact pathway

Potential effects may reach water bodies.
Potential effects may reach ecosystems.
Potential effects may reach affected communities.
Potential effects may reach consumers.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on water bodies?
What is the scale, scope, likelihood and remediability of effects on ecosystems?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Water withdrawal, discharge, quality and catchment-impact records
Biodiversity, habitat and ecosystem-impact evidence
Community engagement, grievance and impact records
Consumer outcome, complaint and product-impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Building services infrastructure including HVAC, boilers, chillers, backup generators, uninterrupted power supply systems and water treatment plant
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots
Process-map item (customers): Pharmaceutical and medical technology companies using provider sites for clinical trials and real-world evidence studies
Process-map item (customers): Care homes, home health agencies and hospices relying on hospital discharge planning and specialist support
Process-map item (emerging_pressures): Investor and payer scrutiny of hospital carbon footprints, anaesthetic gases, inhaler choices, energy procurement and waste segregation

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS E3 Water and marine resourcessearch disclosure cards
ESRS ESRS E2 Pollution for water pollutantssearch disclosure cards
GRI GRI 303 Water and Effluentssearch disclosure cards
SASB SASB Health Care Delivery environmental management and waste topics may partially apply

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Retail energy, refrigeration and medicines logistics emissions covers greenhouse gas emissions and energy use from branches, distribution centres, cold storage, automation, delivery vans, courier contracts and related customer travel to pharmacies.

How it shows up in this industry

Drug retailers operate energy-using high-street and supermarket branches, consultation rooms, secured medicines cabinets, central-fill hubs, distribution centres, cold cabinets, temperature-controlled storage areas, e-commerce platforms and last-mile delivery infrastructure. Energy use, refrigerant leakage, wholesaler deliveries, inter-branch transfers, home delivery and customer travel are relevant greenhouse gas sources.

Why it may be material

Energy and logistics emissions affect utility OPEX, refrigeration and store-refit CAPEX, financing expectations and eligibility for low-carbon procurement by health systems and employers. Refrigerant leakage, fragmented delivery routing and inefficient store estates can raise costs while weakening decarbonisation claims.

Impact pathway

Potential effects may reach the atmosphere.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Emissions, air-quality and atmospheric-impact records linked to the topic
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Funding terms, lender or investor requirements and cost-of-capital analysis
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Delivery vans, courier contracts and last-mile delivery infrastructure for home medicines supply
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Vaccination, testing and minor-ailment service facilities within retail premises

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS E1 climate change mitigation, energy and greenhouse gas emissionssearch disclosure cards
GRI GRI energy and emissions disclosuressearch disclosure cards
SASB SASB Drug Retailers energy management and environmental footprint of retail and distribution operations where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Entity-specific validation required
Impact materiality

Workcard generated from the catalogue

What this topic covers

The environmental impacts of managed care office operations, digital infrastructure, paper communications, travel and electronic equipment life cycles.

How it shows up in this industry

Managed care has a lighter physical footprint than clinical care delivery, but its operations rely on office space, regional service centres, hybrid-working infrastructure, contact centres, purchased cloud computing, data storage, telecommunications, paper mailings and electronic equipment supporting claims, enrolment, portals and analytics.

Why it may be material

The operational environmental footprint is usually less material than member access and compliance topics, but it has a clear impact pathway through energy use, emissions, paper consumption and electronic waste. Purchasers and investors may also request climate and resource-use data from large health plan administrators.

Impact pathway

Potential effects may reach the atmosphere.
Potential effects may reach ecosystems.
Potential effects may reach soil and groundwater.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Customers / end-users, Employees.
The source places the pathway in Own operations, Upstream, Cross value chain.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence shows actual or potential impacts on people or the environment?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on the atmosphere?
What investor expectations or stewardship activity could change the topic's relevance?

Evidence to collect

Emissions, air-quality and atmospheric-impact records linked to the topic
Biodiversity, habitat and ecosystem-impact evidence
Soil and groundwater monitoring, incident and remediation records
Long-term scenario, cumulative-impact and intergenerational analysis
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Claims adjudication platforms, eligibility engines and electronic data interchange gateways connected to hospitals, clinics, laboratories and pharmacies
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (assets): Office space, regional service centres and hybrid-working infrastructure for claims, clinical review, sales and compliance staff
Process-map item (emerging_pressures): Expansion of interoperability, price transparency and real-time prior authorisation requirements under CMS rules and related data standards
Process-map item (emerging_pressures): Increased cyber ransomware targeting health plan data warehouses, claims platforms and third-party administrators

It may be less material when…

Entity-specific evidence does not show meaningful scale, exposure or effects.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant upstream pathway.

Affected stakeholders

Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS Climate change, energy use, resource use and circular economysearch disclosure cards
GRI Emissions, energy, waste and materialssearch disclosure cards
SASB Operational environmental footprint where reported for health care services and technology activities

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The social and financial management of plan affordability, cost-sharing and understandable coverage information affecting members’ ability to obtain needed healthcare.

How it shows up in this industry

Managed care organisations design health benefit products, cost-sharing structures, covered service rules and plan documents for employer, individual, Medicare Advantage, Medicare Part D and Medicaid managed care populations. These choices shape whether members can afford diagnosis, medicines, preventive services and follow-up care without excessive financial strain.

Why it may be material

Benefit affordability and coverage clarity are central to member welfare and purchaser value. Poorly designed or poorly explained benefits can lead to underinsurance, medical debt, complaints, corrective actions and loss of employer or public purchaser confidence.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Licences, brand reputation, government plan contracts, accreditation status and broker distribution relationships
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants
Process-map item (customers): Labour unions, professional associations and affinity groups sponsoring health benefit arrangements
Process-map item (customers): Brokers, benefits consultants and private exchanges advising employers and individuals on plan selection

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS Consumers and end-users: access to services, affordability, non-discrimination and information-related impactssearch disclosure cards
GRI Customer health and safety, customer information and management of impacts on customerssearch disclosure cards
SASB access, affordability, quality and member experience topics

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Prevention of avoidable morbidity, mortality and psychological harm arising from clinical assessment, diagnosis, prescribing, procedures, monitoring, escalation and discharge decisions.

How it shows up in this industry

Health care delivery depends on safe emergency, inpatient, outpatient, surgical, maternity, mental health, rehabilitation and palliative services across hospitals, clinics, imaging centres, laboratories and discharge pathways. Triage, diagnosis, prescribing, monitoring, theatre scheduling, radiotherapy, connected clinical equipment, clinical documentation and quality reporting directly affect patient outcomes, accreditation status, payer contracts and malpractice exposure.

Why it may be material

The core output of the industry is safe clinical care. Avoidable harm, delayed diagnosis, missed deterioration, surgical errors, maternity failures, medication errors and fragmented discharge can lead to morbidity, mortality, compensation schemes, inspection sanctions, payment denials, readmission penalties and loss of patient trust.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Potential effects may reach workers.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Workforce, health and safety, engagement and grievance records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Acute hospitals with operating theatres, emergency departments, intensive care units, wards, maternity units and isolation rooms
Process-map item (assets): Laboratories for pathology, microbiology, blood testing and point-of-care diagnostics
Process-map item (assets): Building services infrastructure including HVAC, boilers, chillers, backup generators, uninterrupted power supply systems and water treatment plant
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

SASB Quality of Care & Patient Satisfaction
ESRS ESRS S4 Consumers and end-users; patient health and safety impacts of servicessearch disclosure cards
GRI GRI 416 Customer Health and Safety, applied to clinical servicessearch disclosure cards

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Controls that preserve potency, sterility and efficacy of temperature-sensitive medicines, vaccines and devices through receiving, warehousing, picking, packing, dispatch, delivery and returns.

How it shows up in this industry

Specialty pharmaceutical hubs and regional distribution centres handle biologics, GLP-1 medicines, vaccines, oncology products and cell and gene therapy kits requiring 2–8 °C, frozen, ultra-low temperature, light-protected or humidity-controlled handling. Validated packaging, temperature-controlled trailers, refrigerated vans, dry ice and liquid nitrogen are central operating assets.

Why it may be material

Temperature excursions can destroy high-value inventory, trigger recalls, breach Good Distribution Practice requirements and undermine specialty distribution contracts. Growth in biologics and vaccines increases validated cold-chain capacity, monitoring and energy requirements.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach workers.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What evidence shows that customer demand is changing?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Workforce, health and safety, engagement and grievance records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Validated cold rooms, freezers, temperature-controlled trailers and refrigerated vans
Process-map item (customers): Specialty pharmacies and home delivery medicine providers
Process-map item (emerging_pressures): Expansion of pharmaceutical serialisation, electronic product tracing and interoperable verification requirements
Process-map item (emerging_pressures): Growth in biologics, GLP-1 medicines, vaccines and cell therapies increasing demand for validated cold-chain capacity
Process-map item (emerging_pressures): Customer and investor pressure to cut diesel fleet emissions, refrigerant leakage and single-use cold-packaging waste

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-users; product health and safety impactssearch disclosure cards
GRI GRI 416 Customer Health and Safetysearch disclosure cards
SASB SASB Health Care Distributors; product safety and supply-chain integrity for temperature-sensitive products

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Controlled-drug stewardship and diversion prevention covers patient and community safeguards for the supply, refusal, storage, reconciliation, destruction and delivery of medicines with dependence, misuse and fatal poisoning pathways.

How it shows up in this industry

Drug retailers handle controlled drugs in branch dispensaries, central-fill hubs and home delivery routes using locked cabinets, restricted access, registers, incident reporting, witnessed destruction and transfer controls. Opioids, sedatives and stimulants create dependence, misuse, overdose, theft and diversion pathways, with heightened enforcement and litigation scrutiny.

Why it may be material

Controlled-drug governance is a distinct material issue because weak legitimacy checks or stock controls can enable community harm, while overly blunt controls can impair legitimate patient access. Failures threaten pharmacy licences, payer contracts, insurance terms and brand trust.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Potential effects may reach workers.
Potential effects may reach emergency responders.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Emergency-response plans, incident logs and responder feedback
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Central-fill dispensing hubs using automated picking, verification and pouch-packing equipment
Process-map item (assets): Wholesale distribution centres, stock rooms and temperature-controlled storage areas for vaccines, insulin and biologics
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Robotic dispensing units, barcode verification systems, electronic prescription service connections and serialisation scanners
Process-map item (customers): Patients requiring specialist handling for high-cost biologics, cold-chain medicines or controlled drugs

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 consumers and end-users: health and safetysearch disclosure cards
ESRS ESRS G1 business conduct where controlled-drug controls are governance-criticalsearch disclosure cards
GRI GRI customer health and safety and compliance-related disclosures where controlled-drug rules are breachedsearch disclosure cards
SASB SASB Drug Retailers controlled substances, opioid dispensing and prescription monitoring controls

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Reliability, transparency and fairness of distribution processes that keep essential medicines, vaccines, devices, diagnostics and emergency supplies available during shortages, recalls, strikes, port delays, demand spikes or other supply constraints.

How it shows up in this industry

Health care distributors sit between medicine and device manufacturers and pharmacies, NHS trusts, hospitals, clinics, care homes and public health agencies. Forecasting, safety-stock settings, expiry rotation, allocation of scarce GLP-1 medicines, vaccines, intensive care products and emergency replenishment directly affect patient access and public health preparedness.

Why it may be material

Service failure can breach manufacturer distribution agreements, public buyer requirements and group purchasing organisation contracts, while unfair or opaque allocation can damage relationships with health systems. High-value medicine inventories also create working-capital exposure, obsolescence and expiry write-offs.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications
Process-map item (customers): Specialty pharmacies and home delivery medicine providers
Process-map item (customers): Veterinary practices and animal health pharmacies
Process-map item (customers): Government stockpiles, public health agencies and emergency preparedness bodies

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Business partners
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-users; access to products and services and health-related impactssearch disclosure cards
GRI GRI 416 Customer Health and Safetysearch disclosure cards
GRI GRI 203 Indirect Economic Impacts where medicine access affects public healthsearch disclosure cards
SASB SASB Health Care Distributors; service reliability, product safety or supply-chain integrity-related aspects

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Management of infection-control systems and antimicrobial use that protect patients, workers, communities and future treatment effectiveness.

How it shows up in this industry

Hospitals, intensive care units, operating theatres, maternity units, dialysis services, endoscopy, laboratories, isolation rooms and rehabilitation facilities rely on decontamination, hand hygiene, sterilisation, environmental cleaning and antibiotic stewardship. Specific hazards include Clostridioides difficile, surgical site infections, catheter-associated infections, multidrug-resistant organisms, sepsis escalation and antimicrobial overuse.

Why it may be material

Healthcare-associated infections increase length of stay, readmissions, consumable use, labour intensity, inspection exposure and litigation. Antimicrobial resistance extends harm beyond a single facility by reducing treatment effectiveness for future patients and increasing public health costs.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach affected communities.
Potential effects may reach water bodies.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Contractors, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What is the scale, scope, likelihood and remediability of effects on workers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Community engagement, grievance and impact records
Water withdrawal, discharge, quality and catchment-impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Sterilisation units, pharmacies, blood banks, medical gas manifolds and bulk oxygen tanks
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls
Process-map item (assets): Ambulance fleets, non-emergency patient transport vehicles, mobile screening units and home care equipment
Process-map item (assets): Clinical licences, accreditation status, payer contracts, provider networks, care pathways, clinical protocols and patient trust as intangible assets
Process-map item (emerging_pressures): Greater regulatory and litigation focus on patient safety, avoidable harm, maternity outcomes, sepsis, waiting lists and duty of candour

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Contractors
Customers / end-users
Employees

Users of the information

Board / management
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-userssearch disclosure cards
ESRS ESRS S1 Own workforce for occupational exposuresearch disclosure cards
GRI GRI 416 Customer Health and Safetysearch disclosure cards
GRI GRI 403 Occupational Health and Safetysearch disclosure cards
SASB Quality of Care & Patient Satisfaction may partially cover infection outcomes

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Medicine access and community pharmacy availability covers the ability of drug retailers to maintain reliable, affordable and timely access to medicines, advice, vaccinations, testing and basic healthcare services across physical branches, repeat-prescription systems and delivery channels.

How it shows up in this industry

Drug retailers act as accessible primary-care points through high-street and supermarket branches, repeat prescriptions, monitored dosage systems, home delivery, vaccinations, testing and minor-ailment services. Online-only pharmacy growth, reimbursement pressure and branch closures can create local medicine deserts, especially for elderly people, disabled patients, carers and people in rural or deprived areas.

Why it may be material

Access performance shapes prescription volume, customer loyalty, public service contracts, preferred pharmacy status and political scrutiny. Underperformance can widen local health inequalities, reduce market share in vulnerable communities and impair the intangible value of the pharmacy brand.

Impact pathway

Potential effects may reach affected communities.
Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What is the scale, scope, likelihood and remediability of effects on consumers?
What evidence shows that customer demand is changing?

Evidence to collect

Community engagement, grievance and impact records
Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Delivery vans, courier contracts and last-mile delivery infrastructure for home medicines supply
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Brand reputation, pharmacy licences, payer network contracts and supplier trading agreements

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS S4 consumers and end-users: access to products and servicessearch disclosure cards
ESRS ESRS S3 affected communities where branch footprint affects local accesssearch disclosure cards
GRI GRI local communities, indirect economic impacts and customer health and safety where access affects health outcomessearch disclosure cards
SASB SASB Drug Retailers access, affordability or pharmacy network indicators may require industry-specific validation

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Parity-specific management of behavioural health and substance use disorder benefits so that plan design, administrative criteria and non-quantitative treatment limitations are comparable with medical or surgical benefits.

How it shows up in this industry

Managed care organisations administer mental health and substance use disorder benefits through plan design, delegated behavioural health administrators, medical necessity criteria, reimbursement methodologies, member communications and compliance documentation. In US managed care markets, scrutiny of the Mental Health Parity and Addiction Equity Act affects Medicaid managed care, Medicare Advantage and employer-sponsored plans, particularly where non-quantitative treatment limitations are applied to behavioural health benefits.

Why it may be material

Parity failures can create unequal treatment conditions for members seeking behavioural health or substance use disorder care even where a plan has a provider network, utilisation management process and pharmacy benefit structure in place. The topic is material because regulators, public purchasers, employers and advocacy groups increasingly examine whether managed care benefit design and administrative controls treat behavioural health comparably with medical or surgical care.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach downstream users.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Downstream-user outcome, complaint and product-use evidence
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants
Process-map item (customers): Individual members buying exchange, marketplace or direct health insurance products
Process-map item (customers): Labour unions, professional associations and affinity groups sponsoring health benefit arrangements
Process-map item (customers): Brokers, benefits consultants and private exchanges advising employers and individuals on plan selection
Process-map item (emerging_pressures): More active enforcement of mental health parity, network adequacy and timely access rules, especially for behavioural health and substance use treatment

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
NGOs / civil society
Regulators

Standards to check

ESRS Consumers and end-users: access, health and non-discrimination impactssearch disclosure cards
GRI Customer health and safety and customer information as indirect anchorssearch disclosure cards
SASB access, affordability and plan performance areas, subject to expert confirmation

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Management of timely, affordable and inclusive access to care, including waiting lists, discharge continuity, communication support and stratified care outcomes across patient groups.

How it shows up in this industry

Patient access, triage, registration, eligibility checks, consent, clinical prioritisation, diagnosis, shared decision-making and discharge logistics determine who receives timely treatment across emergency, elective, outpatient, maternity, mental health, rehabilitation and end-of-life services. Ageing populations, chronic disease, multimorbidity, public payer pressure and health inequality obligations make waiting lists, bed occupancy, follow-up and discharge pathways financially and socially material.

Why it may be material

Delays, affordability barriers and fragmented discharge can worsen disease, increase unpaid care burdens and widen health inequalities. Poor access management can reduce throughput, create waiting-list penalties, trigger inspection findings and weaken payer relationships, while outcome-linked contracts increasingly connect equity and continuity to revenue.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach Indigenous peoples.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Indigenous engagement, consent, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Acute hospitals with operating theatres, emergency departments, intensive care units, wards, maternity units and isolation rooms
Process-map item (assets): Laboratories for pathology, microbiology, blood testing and point-of-care diagnostics
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls
Process-map item (assets): Ambulance fleets, non-emergency patient transport vehicles, mobile screening units and home care equipment
Process-map item (assets): Clinical licences, accreditation status, payer contracts, provider networks, care pathways, clinical protocols and patient trust as intangible assets

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-users, including access to services and non-discriminationsearch disclosure cards
GRI GRI 413 Local Communitiessearch disclosure cards
GRI GRI 416 Customer Health and Safety may partially support this topicsearch disclosure cards
SASB Access for Low-Income Patients; Quality of Care & Patient Satisfaction

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Patient medication safety and counselling covers the controls that prevent incorrect medicines, unsafe self-medication, contraindication failures, inadequate patient information and avoidable treatment failure in retail, online and central-fill pharmacy models.

How it shows up in this industry

Drug retailers dispense prescription-only medicines, over-the-counter medicines, vaccines, biologics, diagnostics and medical devices through branch dispensaries, central-fill hubs, online repeat-prescription platforms and home delivery. Core activities include prescription intake, checks for dose, allergy, interactions and contraindications, barcode verification, pharmacist final checks and patient counselling.

Why it may be material

Medication safety is central to a pharmacy licence, payer network participation and patient trust. Incorrect medicine selection, dose, label, storage advice or counselling can cause patient harm and can lead to professional regulator intervention, litigation, insurance cost increases and loss of repeat-prescription revenue.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What is the scale, scope, likelihood and remediability of effects on downstream users?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): Central-fill dispensing hubs using automated picking, verification and pouch-packing equipment
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Patient medication records, prescription histories, loyalty data and payer adjudication data sets
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 consumers and end-users: health and safety, information-related impacts and access to products and servicessearch disclosure cards
GRI GRI customer health and safety disclosuressearch disclosure cards
SASB Drug Retailers patient health and safety, prescription dispensing and pharmacy quality controls

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The financial and member-access management of pharmacy benefits, formulary placement, rebates, step therapy, speciality medicine controls and high-cost medicine affordability.

How it shows up in this industry

Managed care organisations and affiliated or contracted pharmacy benefit managers design formularies, negotiate rebates, apply step therapy, manage speciality pharmacy networks, administer Medicare Part D benefits and influence mail-order dispensing. Rapid cost growth for GLP-1 medicines and other speciality therapies affects premiums, public budgets, employer purchasers and member cost-sharing design.

Why it may be material

Pharmacy cost trend is a major driver of claims trend and medical cost ratios. Rebate practices, formulary restrictions and speciality pharmacy controls can reduce spend but create access, affordability, antitrust and reputational issues where incentives appear misaligned with clinical need.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants
Process-map item (customers): Labour unions, professional associations and affinity groups sponsoring health benefit arrangements
Process-map item (emerging_pressures): Rising speciality drug and GLP-1 medicine costs pressuring formularies, premiums, rebates and member cost-sharing design
Process-map item (emerging_pressures): More active enforcement of mental health parity, network adequacy and timely access rules, especially for behavioural health and substance use treatment

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Affected communities
Business partners
Customers / end-users
Suppliers

Users of the information

Investors / creditors
Regulators

Standards to check

ESRS Consumers and end-users: access, affordability, health and safety, and information transparencysearch disclosure cards
GRI Customer health and safety and access to medicines-related impacts where applicablesearch disclosure cards
SASB pharmacy benefit management, drug cost trend, member affordability and legal proceedings

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Pharmacy workforce capacity, health and safety covers the labour model and health and safety controls needed to operate dispensaries, central-fill hubs, consultation rooms, vaccination clinics, testing services and delivery operations without excessive workload or preventable harm.

How it shows up in this industry

Drug retailers depend on registered pharmacists, pharmacy technicians, healthcare advisers, delivery drivers, call-centre teams, security and cleaning contractors to run dispensaries, consultation rooms, vaccination clinics, testing, central-fill hand-offs and home delivery. Workforce shortages and expanded clinical services increase locum costs, waiting times, error exposure and staff burnout.

Why it may be material

Pharmacist availability is a binding constraint on branch opening hours, prescription volumes and clinical service revenue. Occupational injuries, violence, infection and hazardous medicine exposure create compensation costs, insurance impacts, absence, turnover and regulatory scrutiny.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Contractors, Customers / end-users, Employees, Trade unions.
The source places the pathway in Own operations.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on workers?
What is the scale, scope, likelihood and remediability of effects on contractors?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Robotic dispensing units, barcode verification systems, electronic prescription service connections and serialisation scanners
Process-map item (assets): Vaccination, testing and minor-ailment service facilities within retail premises

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.

Affected stakeholders

Contractors
Customers / end-users
Employees
Trade unions

Users of the information

Board / management
Regulators

Standards to check

ESRS ESRS S1 own workforce: working conditions, health and safety, work-life balance and trainingsearch disclosure cards
GRI GRI occupational health and safety, employment and training disclosuressearch disclosure cards
SASB SASB Drug Retailers workforce health, safety and service quality aspects where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The impact of provider network design, monitoring and payment incentives on members’ timely, geographically reachable and culturally competent access to healthcare.

How it shows up in this industry

Managed care companies contract, credential and monitor hospitals, physicians, pharmacies, laboratories and ancillary providers. Network tiering, reimbursement rates, capitation arrangements, value-based contracts and provider directory management influence whether members can find timely in-network care, particularly in rural, low-income, specialist and behavioural health markets.

Why it may be material

Provider network sufficiency is a regulated condition for Medicare Advantage, Medicaid managed care and many state-licensed products, and is also a major determinant of claims cost and enrolment competitiveness. Inadequate networks or inaccurate directories can trigger sanctions, litigation, out-of-network claims costs and purchaser dissatisfaction.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach downstream users.
Potential effects may reach Indigenous peoples.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Downstream-user outcome, complaint and product-use evidence
Indigenous engagement, consent, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Licences, brand reputation, government plan contracts, accreditation status and broker distribution relationships
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants
Process-map item (customers): Individual members buying exchange, marketplace or direct health insurance products

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Business partners
Customers / end-users

Users of the information

Investors / creditors
Local authorities
Regulators

Standards to check

ESRS Consumers and end-users: access to services, vulnerable groups and service qualitysearch disclosure cards
GRI Customer health and safety and local community access impactssearch disclosure cards
SASB provider network quality, access, affordability and plan performance

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The management of quality, member experience, health equity and population health outcomes that influence plan performance and financial returns.

How it shows up in this industry

Managed care plans run care management, chronic disease programmes, maternity support, behavioural health navigation, high-cost case management and quality reporting using claims histories, encounter data, demographic data and provider performance measures. Star Ratings, HEDIS, CAHPS and accreditation influence bonus payments, enrolment, market access and government contract renewal.

Why it may be material

Quality and health equity performance can materially affect Medicare Advantage bonus payments, member enrolment, employer and public purchaser retention, accreditation, corrective actions and brand value. Poor demographic data or inequitable outcomes can increase avoidable utilisation and claims costs in high-need populations.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach downstream users.
Potential effects may reach Indigenous peoples.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Downstream-user outcome, complaint and product-use evidence
Indigenous engagement, consent, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Provision, claim, penalty, remediation and contingent-liability records
Process-map item (assets): Claims adjudication platforms, eligibility engines and electronic data interchange gateways connected to hospitals, clinics, laboratories and pharmacies
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS Consumers and end-users: access, health and safety, equal treatment, vulnerable groups and service qualitysearch disclosure cards
GRI Customer health and safety, non-discrimination and local community health impacts where applicablesearch disclosure cards
SASB quality ratings, access, customer satisfaction and plan performance measures

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The effects and governance of utilisation management and denial processes on timely access to clinically appropriate care, member wellbeing and fair treatment.

How it shows up in this industry

Managed care plans process medical, pharmacy, dental, vision and behavioural health claims and conduct utilisation management using medical necessity criteria, clinical policy libraries, nurse review teams, claims adjudication platforms and appeals workflows. These processes determine whether surgery, rehabilitation, diagnostics, home care, medicines and discharge support proceed without delay.

Why it may be material

Coverage determinations and utilisation controls directly influence medical cost ratios, reserve adequacy and member outcomes. Inappropriate or slow denials can create untreated illness, family administrative strain, litigation, sanctions, Star Rating deterioration and loss of government or employer plan contracts.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Claims adjudication platforms, eligibility engines and electronic data interchange gateways connected to hospitals, clinics, laboratories and pharmacies
Process-map item (assets): Actuarial models, risk-scoring models, utilisation management rules, formularies and clinical policy libraries
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (assets): Office space, regional service centres and hybrid-working infrastructure for claims, clinical review, sales and compliance staff
Process-map item (customers): Members’ families, carers and authorised representatives who interact with plan services and appeals processes

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
Regulators

Standards to check

ESRS Consumers and end-users: health and safety, access, complaint mechanisms, non-discrimination and information-related impactssearch disclosure cards
GRI Customer health and safety and grievance mechanismssearch disclosure cards
SASB quality of care, member complaints, claims handling and plan performance metrics

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Health, safety, training and workforce capacity management for high-throughput pharmaceutical distribution centres, automated warehouses and delivery operations.

How it shows up in this industry

High-throughput distribution centres operate automated picking lines, conveyors, robotics, palletisers, barcode stations, cold rooms, segregated storage zones and night-shift fulfilment. Warehouse labour, licensed pharmacists, drivers, security staff and temporary agency workers handle medicines, devices, cold-chain materials, controlled substances and returns under service-level pressure.

Why it may be material

Injury rates, labour availability and automation safety affect fulfilment capacity, workers' compensation costs, insurance premiums and customer service levels. Training failures can also undermine Good Distribution Practice quality systems and increase deviation management costs.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach emergency responders.
Affected stakeholder groups identified in the source include Contractors, Employees, Trade unions.
The source places the pathway in Own operations.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on workers?
What is the scale, scope, likelihood and remediability of effects on contractors?
What is the scale, scope, likelihood and remediability of effects on emergency responders?
What technology changes could alter the topic's impacts or financial effects?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Emergency-response plans, incident logs and responder feedback
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Revenue, demand, pricing and market-access analysis linked to the topic
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Warehouse management, enterprise resource planning, serialisation and track-and-trace platforms
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications
Process-map item (customers): Veterinary practices and animal health pharmacies
Process-map item (customers): Government stockpiles, public health agencies and emergency preparedness bodies

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.

Affected stakeholders

Contractors
Employees
Trade unions

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S1 Own workforce; health and safety, working conditions and trainingsearch disclosure cards
GRI GRI 403 Occupational Health and Safetysearch disclosure cards
GRI GRI 404 Training and Educationsearch disclosure cards
SASB SASB Health Care Distributors; workforce health and safety where financially material

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Management of workforce supply, safe staffing, worker protection, wellbeing, training and retention across clinical, ambulance, laboratory and facilities services.

How it shows up in this industry

Doctors, nurses, midwives, pharmacists, laboratory staff, therapists, care assistants, porters, cleaners, security teams, ambulance crews, laundry workers and facilities staff work around infectious aerosols, sharps, biological waste, cytotoxic medicines, ionising radiation, cleaning chemicals, manual handling and high-pressure shift patterns. Staffing shortages and agency reliance directly affect bed occupancy, theatre utilisation, discharge pathways and service continuity.

Why it may be material

Labour is a dominant operating cost and a constraint on safe capacity in hospitals, clinics, laboratories and home care interfaces. Shortages, fatigue, injury and poor retention increase agency spend, training cost, service disruption, worker compensation, inspection exposure and patient safety pressures.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach supply-chain workers.
Potential effects may reach consumers.
Affected stakeholder groups identified in the source include Contractors, Customers / end-users, Employees, Trade unions.
The source places the pathway in Own operations, Upstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on workers?
What is the scale, scope, likelihood and remediability of effects on contractors?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Supplier workforce, audit, grievance and remediation records
Consumer outcome, complaint and product-impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls
Process-map item (assets): Clinical licences, accreditation status, payer contracts, provider networks, care pathways, clinical protocols and patient trust as intangible assets
Process-map item (customers): Patients receiving emergency, elective, maternity, mental health, rehabilitation, long-term and end-of-life care
Process-map item (customers): Public payers such as national health services, Medicare and Medicaid-type schemes, social insurance funds and local authorities

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream pathway.

Affected stakeholders

Contractors
Customers / end-users
Employees
Trade unions

Users of the information

Board / management
Regulators

Standards to check

ESRS ESRS S1 Own workforce, including health and safety, working conditions and trainingsearch disclosure cards
GRI GRI 401 Employmentsearch disclosure cards
GRI GRI 403 Occupational Health and Safetysearch disclosure cards
GRI GRI 404 Training and Educationsearch disclosure cards
SASB Employee Health & Safety; Employee Recruitment, Development & Retention

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Cold-chain integrity and high-cost medicine resilience covers controls for preserving the safety, efficacy and financial value of temperature-sensitive and high-cost medicines from receiving through storage, dispensing and home delivery.

How it shows up in this industry

Drug retailers increasingly dispense vaccines, insulin, biologics, biosimilars and GLP-1 medicines through branches, distribution centres, central-fill hubs and home delivery. These products need refrigerated storage, validated transport packaging, temperature monitors, excursion assessment and quarantine decisions, with high unit values and payer authorisation workflows amplifying financial exposure.

Why it may be material

Temperature excursions can compromise medicine efficacy and create high-value write-offs, reimbursement disputes, recall costs and patient safety exposure. Capacity constraints in cold cabinets and distribution centres can limit participation in vaccination programmes and specialist medicine growth.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What evidence shows that customer demand is changing?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): Wholesale distribution centres, stock rooms and temperature-controlled storage areas for vaccines, insulin and biologics
Process-map item (assets): Delivery vans, courier contracts and last-mile delivery infrastructure for home medicines supply
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (customers): Walk-in retail customers buying prescription medicines, over-the-counter medicines, health and beauty products and medical devices

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Business partners
Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 health and safety of consumers and end-userssearch disclosure cards
ESRS ESRS E1 where refrigeration energy and refrigerants are relevantsearch disclosure cards
GRI GRI customer health and safety, energy and emissions disclosures where relevantsearch disclosure cards
SASB SASB Drug Retailers product safety and supply chain quality aspects

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Business-model dependent
Moderate industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Safety and emergency controls for transporting hazardous medicines, medical gases, dry ice, lithium batteries and other regulated materials through health care distribution networks.

How it shows up in this industry

Distribution networks use road, courier and air freight for cytotoxic medicines, flammable aerosols, disinfectants, medical gases, lithium batteries, dry ice and liquid nitrogen. Secure and temperature-controlled lanes often combine service urgency with dangerous-goods controls at depot docks, hospital delivery bays and freight hand-offs under ADR, UN and IATA requirements.

Why it may be material

Transport incidents can produce injury claims, environmental clean-up costs, cargo loss, route disruption, regulatory penalties and insurance premium increases. Compliance failures can also interrupt urgent medicine lanes and undermine service-level performance with hospitals and clinics.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach affected communities.
Potential effects may reach emergency responders.
Potential effects may reach ecosystems.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Contractors, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on workers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Community engagement, grievance and impact records
Emergency-response plans, incident logs and responder feedback
Biodiversity, habitat and ecosystem-impact evidence
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Operating-cost records and budgets linked to the topic
Revenue, demand, pricing and market-access analysis linked to the topic
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Reverse-logistics facilities for returns, recalls, expired medicines and damaged stock
Process-map item (customers): Government stockpiles, public health agencies and emergency preparedness bodies
Process-map item (customers): Medical device distributors, laboratory suppliers and secondary wholesalers
Process-map item (emerging_pressures): More frequent extreme heat, storms and floods disrupting transport lanes and warehouse resilience
Process-map item (emerging_pressures): Restrictions on PFAS, PVC, expanded polystyrene and other materials used in medical and cold-chain packaging

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Business partners
Contractors
Customers / end-users
Employees

Users of the information

Local authorities
Regulators

Standards to check

ESRS ESRS S1 Own workforcesearch disclosure cards
ESRS ESRS S3 Affected communitiessearch disclosure cards
ESRS ESRS E2 Pollution where releases occursearch disclosure cards
GRI GRI 403 Occupational Health and Safetysearch disclosure cards
GRI GRI 306 Waste where spill residues arisesearch disclosure cards
SASB SASB Health Care Distributors; product safety and operational incident proxies

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The downstream social effects of claims, credentialling, payment integrity and reporting requirements on care providers and the patients they serve.

How it shows up in this industry

Managed care plans interact with hospitals, physicians, pharmacies, therapists, laboratories and home health providers through provider contracts, credentialling files, fee schedules, capitation arrangements, claims edits, coding reviews and value-based care reporting requirements. These processes can shift administrative work and cash-flow pressure onto care delivery organisations.

Why it may be material

Administrative burden on providers can reduce clinical time, delay authorisation or referral processes, strain smaller practices and weaken provider participation in networks. It also creates provider disputes, arbitration, regulatory complaints and reputational damage with clinicians and public purchasers.

Impact pathway

Potential effects may reach supply-chain workers.
Potential effects may reach contractors.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on supply-chain workers?
What evidence shows that customer demand is changing?

Evidence to collect

Supplier workforce, audit, grievance and remediation records
Contractor working-condition, incident and engagement records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Revenue, demand, pricing and market-access analysis linked to the topic
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Claims adjudication platforms, eligibility engines and electronic data interchange gateways connected to hospitals, clinics, laboratories and pharmacies
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (assets): Office space, regional service centres and hybrid-working infrastructure for claims, clinical review, sales and compliance staff
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Suppliers

Users of the information

Board / management
Regulators

Standards to check

ESRS Workers in the value chain and business conduct in relationships with business partnerssearch disclosure cards
GRI Supplier and business-partner impact management; customer health and safety where patient access is affectedsearch disclosure cards
SASB provider relationships, claims processing and quality of care proxies

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Business-model dependent
Entity-specific validation required
Double materiality

Workcard generated from the catalogue

What this topic covers

Local community effects from distribution depot operations, vehicle movements, delivery bay activity and logistics park footprints.

How it shows up in this industry

Health care distributors operate high-bay warehouses, logistics parks, route-planned vans and lorries, and frequent deliveries to pharmacies, hospitals and clinics. Local impacts arise from traffic congestion, noise, idling emissions, road safety harms, stormwater run-off and light pollution around depots and delivery bays.

Why it may be material

Impacts are most material where large depots operate near residential areas, hospitals or congested urban routes and where same-day or night-time delivery schedules increase local disturbance. Poor management can affect planning permission, depot expansion and community acceptance.

Impact pathway

Potential effects may reach affected communities.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach water bodies.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What is the scale, scope, likelihood and remediability of effects on workers?
What civil-society scrutiny or campaigns could change the topic's relevance?

Evidence to collect

Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Water withdrawal, discharge, quality and catchment-impact records
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Reverse-logistics facilities for returns, recalls, expired medicines and damaged stock
Process-map item (customers): Retail pharmacy chains and independent community pharmacies
Process-map item (customers): Specialty pharmacies and home delivery medicine providers
Process-map item (external_impacts): Greenhouse gas emissions from diesel lorries, air freight for urgent medicines and electricity used by refrigerated warehouses
Process-map item (external_impacts): Community health harms where controlled substances are diverted or suspicious orders are not stopped

It may be less material when…

Entity-specific evidence does not show meaningful scale, exposure or effects.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Local authorities
Regulators

Standards to check

ESRS ESRS S3 Affected communities and pollution-related local impactssearch disclosure cards
GRI GRI local community impacts and emissions where logistics activity affects nearby residentssearch disclosure cards
SASB Local logistics amenity impacts are not a clear Health Care Distributors topic

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Business-model dependent
Entity-specific validation required
Double materiality

Workcard generated from the catalogue

What this topic covers

Management of local community effects from healthcare campuses, expansions, transport flows, emergency operations, service reconfiguration and community benefit activities.

How it shows up in this industry

Large hospital campuses, emergency departments, ambulance bays, helipads, diagnostic centres and construction projects can affect neighbouring communities through traffic congestion, parking pressure, sirens, noise, lighting, visual amenity, stormwater run-off and disruption during expansion or service reconfiguration. Providers can also deliver community benefits through employment, training, prevention, public health surveillance and emergency response capacity.

Why it may be material

Community impacts are material for large campuses, urban hospitals, helipad-equipped acute sites and organisations changing service footprints. Poor engagement can delay planning approvals, increase project cost and weaken public trust, while strong community benefit can support social licence and local health outcomes.

Impact pathway

Potential effects may reach affected communities.
Potential effects may reach workers.
Potential effects may reach consumers.
Potential effects may reach ecosystems.
Potential effects may reach water bodies.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may affect demand, pricing, market access or product and service revenue.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What is the scale, scope, likelihood and remediability of effects on workers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Consumer outcome, complaint and product-impact records
Biodiversity, habitat and ecosystem-impact evidence
Water withdrawal, discharge, quality and catchment-impact records
Capital plans, asset adaptation budgets and investment approvals
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Revenue, demand, pricing and market-access analysis linked to the topic
Process-map item (customers): Public payers such as national health services, Medicare and Medicaid-type schemes, social insurance funds and local authorities
Process-map item (customers): Referring general practitioners, specialists, urgent care centres and community health providers
Process-map item (customers): Care homes, home health agencies and hospices relying on hospital discharge planning and specialist support
Process-map item (emerging_pressures): Shortages of nurses, doctors, allied health professionals and care workers increasing wage pressure, agency spend and service disruption
Process-map item (emerging_pressures): Investor and payer scrutiny of hospital carbon footprints, anaesthetic gases, inhaler choices, energy procurement and waste segregation

It may be less material when…

Entity-specific evidence does not show meaningful scale, exposure or effects.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users
Employees

Users of the information

Board / management
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS S3 Affected communitiessearch disclosure cards
ESRS ESRS E2 or E4 may be relevant for environmental pathwayssearch disclosure cards
GRI GRI 413 Local Communitiessearch disclosure cards
GRI GRI 203 Indirect Economic Impacts may be relevant for community benefitsearch disclosure cards
SASB SASB Health Care Delivery has no direct community amenity topic; issue may be entity-specific

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Emerging issue
Moderate industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Safe and low-carbon direct-to-patient medicines delivery covers courier qualification, identity and handover controls, temperature management, packaging choices, failed-delivery procedures, confidentiality and delivery emissions for dispensed medicines supplied to patients outside the branch.

How it shows up in this industry

Drug retailers are expanding e-commerce, repeat-prescription ordering, kerbside collection, postal fulfilment and courier delivery. Direct-to-patient supply must maintain prescription confidentiality, cold-chain integrity, controlled-drug security, age-restricted handover and safe counselling while also addressing packaging and last-mile emissions from delivery vans and courier networks.

Why it may be material

Online-only pharmacy growth and demand for home medicines supply shift patient-safety controls from the branch counter into delivery routes and courier contracts. The model also raises visible low-carbon logistics and packaging expectations from health systems, corporate customers and investors.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach the atmosphere.
Affected stakeholder groups identified in the source include Affected communities, Contractors, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What evidence shows that customer demand is changing?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Emissions, air-quality and atmospheric-impact records linked to the topic
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Patient medication records, prescription histories, loyalty data and payer adjudication data sets
Process-map item (assets): Delivery vans, courier contracts and last-mile delivery infrastructure for home medicines supply
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Contractors
Customers / end-users
Suppliers

Users of the information

Board / management
Regulators

Standards to check

ESRS ESRS E1 climate changesearch disclosure cards
ESRS ESRS S4 consumers and end-userssearch disclosure cards
ESRS ESRS G1 business conductsearch disclosure cards
GRI GRI emissions, customer health and safety, and supplier-related disclosuressearch disclosure cards
SASB SASB Drug Retailers topics on patient safety, supply chain and distribution, where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Emerging issue
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Safe, equitable and accountable expansion of telehealth, remote monitoring and hospital-at-home pathways.

How it shows up in this industry

Telehealth, remote monitoring, patient portals and hospital-at-home models shift parts of acute and post-acute care from wards into homes. Discharge logistics involving home oxygen, mobility aids, community nursing, care packages and care homes change clinical escalation, equipment support, family responsibilities and access for patients without reliable connectivity, digital confidence or private space.

Why it may be material

Virtual and home-based care can reduce bed pressure and improve convenience, but it transfers monitoring, equipment and communication dependencies into domestic settings. Regulatory and litigation attention is rising where remote pathways contribute to missed deterioration, inequitable access or fragmented handover.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach workers.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Capital plans, asset adaptation budgets and investment approvals
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Acute hospitals with operating theatres, emergency departments, intensive care units, wards, maternity units and isolation rooms
Process-map item (assets): Laboratories for pathology, microbiology, blood testing and point-of-care diagnostics
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls
Process-map item (assets): Ambulance fleets, non-emergency patient transport vehicles, mobile screening units and home care equipment

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users
Employees

Users of the information

Investors / creditors
Local authorities
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-users: access, quality and non-discriminationsearch disclosure cards
GRI GRI 416 Customer Health and Safety and access to servicessearch disclosure cards
SASB quality of care and patient satisfaction

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Emerging issue
Entity-specific validation required
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Integration of climate-related health burdens and climate-related disaster disruption into managed care actuarial modelling, reserve setting, targeted member outreach, care management and climate-specific continuity planning.

How it shows up in this industry

Managed care plans price premiums, set reserves, manage risk adjustment and run high-cost case management for Medicare Advantage, Medicaid, individual and employer populations. Heat illness, wildfire smoke, flooding, infectious disease shifts and climate-related provider disruption can increase emergency care, medicine needs, behavioural health demand and care-continuity challenges, particularly for older, chronically ill, low-income and geographically concentrated members.

Why it may be material

Climate-sensitive morbidity can increase claims trend, catastrophic case exposure, stop-loss or reinsurance costs and reserve volatility, especially where membership is concentrated in heat, flood, wildfire smoke or vector-borne disease geographies. Plans that integrate climate scenarios into actuarial pricing, member outreach and climate-specific care-continuity arrangements can protect members, margins and public purchaser confidence without substituting for broader access, parity or quality programmes.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What scientific evidence or consensus could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Claims adjudication platforms, eligibility engines and electronic data interchange gateways connected to hospitals, clinics, laboratories and pharmacies
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (assets): Office space, regional service centres and hybrid-working infrastructure for claims, clinical review, sales and compliance staff

It may be less material when…

Entity-specific evidence does not show meaningful scale, exposure or effects.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS Climate change adaptation; consumers and end-users for climate-related health access effectssearch disclosure cards
GRI Possible links to financial implications of climate change and customer health impactssearch disclosure cards
SASB Managed Care does not clearly isolate climate-sensitive claims and climate-related care-continuity adaptation

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The governance and social impact of algorithm-assisted decisions that affect care access, claims payment, fraud investigation and member targeting.

How it shows up in this industry

Managed care companies use eligibility engines, claims adjudication platforms, utilisation management rules, formularies, clinical policy libraries, actuarial models, risk scoring, fraud analytics and care management algorithms across claims platforms and data warehouses. These systems can influence coverage determinations, member targeting and provider scrutiny at very large scale.

Why it may be material

Automated prior authorisation and claims denial systems directly shape access to surgery, medicines, diagnostics, rehabilitation and home care. Regulators, purchasers and courts are increasingly focused on explainability, clinical appropriateness, denial letters and meaningful clinician oversight.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Provision, claim, penalty, remediation and contingent-liability records
Operating-cost records and budgets linked to the topic
Revenue, demand, pricing and market-access analysis linked to the topic
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Claims adjudication platforms, eligibility engines and electronic data interchange gateways connected to hospitals, clinics, laboratories and pharmacies
Process-map item (assets): Actuarial models, risk-scoring models, utilisation management rules, formularies and clinical policy libraries
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (assets): Office space, regional service centres and hybrid-working infrastructure for claims, clinical review, sales and compliance staff
Process-map item (emerging_pressures): Greater scrutiny of automated prior authorisation, claims denial algorithms and clinical decision-support tools, including demands for explainability and clinician oversight

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Business partners
Customers / end-users

Users of the information

Board / management
Investors / creditors
NGOs / civil society
Regulators

Standards to check

ESRS Consumers and end-users; business conduct and governance of impacts where decision systems affect fair treatmentsearch disclosure cards
GRI Customer health and safety, non-discrimination and privacy-related disclosures where relevantsearch disclosure cards
SASB claims handling, quality of care and data security proxies

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The conduct and compliance governance needed to operate health plan products, public programme contracts, employer plan administration and member services within applicable healthcare and insurance rules.

How it shows up in this industry

Managed care organisations operate under dense federal and state oversight, including Affordable Care Act requirements, ERISA rules for many employer-sponsored plans, CMS regulations for Medicare Advantage, Medicare Part D and Medicaid managed care, state insurance commissioner oversight, No Surprises Act requirements, solvency frameworks and accreditation expectations from bodies such as NCQA and URAC.

Why it may be material

Licences, government contracts, accreditation status and public trust are core assets in managed care. Weak conduct controls can lead to fines, corrective action plans, sanctions, rate filing obstacles, contract restrictions, exclusion from government programmes and reputational harm with employers, brokers and members.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach workers.
Affected stakeholder groups identified in the source include Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Office space, regional service centres and hybrid-working infrastructure for claims, clinical review, sales and compliance staff
Process-map item (customers): Individual members buying exchange, marketplace or direct health insurance products
Process-map item (customers): Medicare Advantage, Medicare Part D and Medicaid managed care beneficiaries enrolled through government-sponsored plans

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Local authorities
Regulators

Standards to check

ESRS Business conduct, corruption and bribery, compliance management and consumer-related conduct impactssearch disclosure cards
GRI Anti-corruption, compliance with laws and regulations, and governance disclosuressearch disclosure cards
SASB legal proceedings, regulatory compliance and plan performance

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Business ethics and pharmacy regulatory compliance covers the conduct, controls and accountability needed to comply with medicines, controlled-drug, pharmacy premises, professional registration, reimbursement, advertising, pharmacovigilance and anti-bribery requirements in drug retail operations.

How it shows up in this industry

Drug retailers operate under pharmacy registration, pharmacist professional standards, medicines advertising rules, controlled-drug regulations, payer adjudication requirements, public health service contracts and pharmacovigilance obligations. Business conduct issues can arise in claims submission, dispensing fee practices, supplier rebates, prescription inducements, controlled-drug records, medicine advertising or failure to escalate safety signals.

Why it may be material

Compliance is fundamental to pharmacy licences, public reimbursement, payer network inclusion and customer trust. Failures can lead to fines, licence restrictions, contract termination, repayment of claims, litigation, insurance cost increases and loss of professional credibility.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach workers.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Brand reputation, pharmacy licences, payer network contracts and supplier trading agreements
Process-map item (customers): Public and private health insurers, pharmacy benefit managers and national health services reimbursing dispensed medicines

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 business conduct, corruption and bribery, protection of whistle-blowers and supplier relationship governancesearch disclosure cards
GRI GRI anti-corruption, anti-competitive behaviour and compliance-related disclosuressearch disclosure cards
SASB SASB Drug Retailers regulatory compliance, controlled substances, patient safety and business ethics aspects

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance of lawful, ethical and controlled distribution operations, including regulated authorisations, quality systems, anti-bribery controls, internal audits, whistleblowing and commercial conduct in tenders, rebates, chargebacks and manufacturer contracts.

How it shows up in this industry

Health care distributors operate under Good Distribution Practice, MHRA wholesale dealer authorisation, FDA supply-chain security expectations, national medicines verification systems, controlled-substance rules, hazardous transport requirements and data protection regimes. They also participate in tenders, manufacturer distribution agreements, payer and group purchasing organisation arrangements and rebate or chargeback processes.

Why it may be material

Regulatory non-compliance can suspend licences, block product flows, terminate manufacturer mandates and create civil or criminal liability. Bribery, fraud or weak internal controls in tendering, rebates, chargebacks and quality records can directly threaten revenue and trust with hospitals, pharmacies and regulators.

Impact pathway

Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications
Process-map item (external_impacts): Traffic congestion, noise, idling emissions and road safety risks around distribution depots and hospital delivery bays
Process-map item (financial_channels): Fines, licence suspension or criminal liability for Good Distribution Practice failures, falsified medicines or controlled-substance diversion
Process-map item (financial_channels): Litigation and settlement costs linked to opioid distribution, product recalls, data breaches or unsafe handling

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 Business conduct; corruption, bribery, compliance and corporate culturesearch disclosure cards
GRI GRI 205 Anti-corruptionsearch disclosure cards
GRI GRI 206 Anti-competitive Behavioursearch disclosure cards
GRI GRI 2 governance and compliance disclosuressearch disclosure cards
SASB SASB Health Care Distributors; business ethics and regulatory compliance aspects of distribution integrity

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Governance of sensitive patient data, cyber-dependent clinical operations and connected medical device security.

How it shows up in this industry

Health care delivery depends on electronic health records, clinical decision support platforms, patient portals, telehealth infrastructure, scheduling systems, cloud hosting, diagnostic imaging, laboratory systems, pharmacy systems and connected devices such as infusion pumps, ventilators and monitors. Ransomware, device compromise or data breaches can disrupt emergency care, diagnostics, prescribing, theatre scheduling, remote monitoring, billing and claims submission.

Why it may be material

Clinical data breaches create regulatory penalties and litigation, while downtime can halt imaging, laboratories, pharmacies, theatre lists and claims submission. Cyber insurance exclusions, recovery costs and capital needs for secure digital infrastructure create clear financial exposure, and system unavailability can directly harm patients.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach workers.
Potential effects may reach affected communities.
Potential effects may reach emergency responders.
Potential effects may reach downstream users.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Workforce, health and safety, engagement and grievance records
Community engagement, grievance and impact records
Emergency-response plans, incident logs and responder feedback
Downstream-user outcome, complaint and product-use evidence
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls
Process-map item (assets): Ambulance fleets, non-emergency patient transport vehicles, mobile screening units and home care equipment
Process-map item (assets): Clinical licences, accreditation status, payer contracts, provider networks, care pathways, clinical protocols and patient trust as intangible assets
Process-map item (customers): Patients receiving emergency, elective, maternity, mental health, rehabilitation, long-term and end-of-life care

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-users for privacy and service impactssearch disclosure cards
ESRS ESRS G1 for governance controls may be relevantsearch disclosure cards
GRI GRI 418 Customer Privacy, with entity-specific clinical system resilience disclosuressearch disclosure cards
SASB Patient Privacy & Electronic Health Records

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Integrity of clinical documentation, coding, billing, claims, quality reporting, controlled drug custody, payer interactions, accreditation compliance and anti-fraud controls.

How it shows up in this industry

Health care providers perform eligibility checks, clinical documentation, coding, billing, claims submission, quality reporting, prescribing, controlled drug custody and regulated returns under facility licensing, professional registration, payer contracts, accreditation regimes and controlled drugs legislation. Payers can deny claims, apply clawbacks or impose penalties for coding errors, billing non-compliance, unnecessary procedures or hospital-acquired conditions.

Why it may be material

Revenue integrity depends on accurate coding and compliant billing under tariffs, diagnosis-related groups, capitation and payer contracts. Weak controls can trigger repayments, penalties, exclusion from provider networks, criminal or civil investigations, bond covenant concerns and loss of public trust.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach workers.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What is the scale, scope, likelihood and remediability of effects on workers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Workforce, health and safety, engagement and grievance records
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls
Process-map item (assets): Clinical licences, accreditation status, payer contracts, provider networks, care pathways, clinical protocols and patient trust as intangible assets
Process-map item (customers): Pharmaceutical and medical technology companies using provider sites for clinical trials and real-world evidence studies
Process-map item (emerging_pressures): Investor and payer scrutiny of hospital carbon footprints, anaesthetic gases, inhaler choices, energy procurement and waste segregation

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 Business conduct, including corruption, compliance culture and whistleblowing where relevantsearch disclosure cards
GRI GRI 205 Anti-corruptionsearch disclosure cards
GRI GRI 206 Anti-competitive Behaviour and governance disclosuressearch disclosure cards
GRI GRI 416 where overuse affects patient safetysearch disclosure cards
SASB Pricing & Billing Transparency; Management of Controlled Substances; Fraud, Waste and Abuse where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance, analytics, customer due diligence, inventory reconciliation and escalation controls that prevent controlled medicines from being diverted from legitimate wholesale distribution channels into misuse or illicit resale.

How it shows up in this industry

Health care distributors receive, store and supply opioids, stimulants, benzodiazepines and other controlled medicines to pharmacies, hospitals, clinics and authorised dispensers. The material issue is the governance of suspicious-order monitoring, controlled-product customer due diligence, inventory reconciliation and escalation controls for medicines with high misuse and diversion potential.

Why it may be material

Diversion failures in controlled-medicine distribution have been associated with major settlements, licence restrictions, criminal exposure and intensive monitoring arrangements. The issue links board-level governance, order analytics and customer due diligence to community health impacts from medicines diverted outside legitimate clinical channels.

Impact pathway

Potential effects may reach affected communities.
Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach emergency responders.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may affect access to finance, funding terms or the cost of capital.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Community engagement, grievance and impact records
Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Emergency-response plans, incident logs and responder feedback
Provision, claim, penalty, remediation and contingent-liability records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Funding terms, lender or investor requirements and cost-of-capital analysis
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Controlled-substance vaults, cages, safes and segregated quarantine areas
Process-map item (assets): Validated cold rooms, freezers, temperature-controlled trailers and refrigerated vans
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications
Process-map item (customers): Retail pharmacy chains and independent community pharmacies

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS G1 Business conductsearch disclosure cards
ESRS ESRS S3 Affected communitiessearch disclosure cards
ESRS ESRS S4 Consumers and end-users where public health is affectedsearch disclosure cards
GRI GRI 416 Customer Health and Safetysearch disclosure cards
GRI GRI 2 governance and compliance disclosuressearch disclosure cards
SASB SASB Health Care Distributors; controlled substances and drug supply-chain integrity

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Protection and recovery of digital systems that support medicine ordering, warehouse automation, serialisation, customer data, delivery confirmation and recall communications.

How it shows up in this industry

Health care distributors rely on customer ordering portals, electronic data interchange links, e-procurement integrations, warehouse management systems, robotics, conveyors, barcode scanning, serialisation databases and electronic proof of delivery. A cyber incident can stop order fulfilment, corrupt traceability records, delay recalls or expose GDPR or HIPAA-regulated information.

Why it may be material

Cyber disruption can halt 24-hour fulfilment, trigger data breach liabilities, raise cyber insurance costs and cause contract losses with hospitals, pharmacies and manufacturers. Automation and interoperable traceability systems expand the attack surface and connect governance controls directly to patient access and safety.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What technology changes could alter the topic's impacts or financial effects?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Community engagement, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Warehouse management, enterprise resource planning, serialisation and track-and-trace platforms
Process-map item (assets): Customer ordering portals, electronic data interchange links and e-procurement integrations with hospitals and pharmacies
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications
Process-map item (emerging_pressures): Expansion of pharmaceutical serialisation, electronic product tracing and interoperable verification requirements

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 Business conductsearch disclosure cards
ESRS ESRS S4 Consumers and end-users where data and service continuity affect customerssearch disclosure cards
GRI GRI 418 Customer Privacysearch disclosure cards
SASB SASB Health Care Distributors; Data Security

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

The protection of sensitive health plan data and digital service continuity across owned systems and third-party data processors.

How it shows up in this industry

Managed care operations depend on claims adjudication platforms, eligibility engines, EDI gateways, member portals, mobile applications, call centres, data warehouses and cloud services containing claims histories, diagnoses, pharmacy data, demographic information and prior authorisation records. Sensitive data move between insurers, pharmacy benefit managers, analytics vendors, third-party administrators and providers under business associate or data processing agreements.

Why it may be material

Ransomware incidents and privacy breaches can interrupt claims payment, enrolment, authorisation, care management and provider portals, while exposing highly sensitive health and financial data. Consequences include remediation OPEX, breach notification, credit monitoring, litigation, regulatory penalties, cyber insurance escalation and loss of purchaser trust.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach supply-chain workers.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees, Suppliers, Value chain workers.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Supplier workforce, audit, grievance and remediation records
Community engagement, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Claims adjudication platforms, eligibility engines and electronic data interchange gateways connected to hospitals, clinics, laboratories and pharmacies
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (assets): Cybersecurity infrastructure, identity management systems, audit logs, encryption tools and incident response capabilities

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Employees
Suppliers
Value chain workers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS Consumers and end-users: privacy and information-related impacts, plus business conduct controlssearch disclosure cards
GRI Customer privacysearch disclosure cards
SASB customer privacy and data security

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance and due diligence for critical outsourced parties that support claims, enrolment, pharmacy benefits, analytics, distribution, member communications and care management.

How it shows up in this industry

Managed care workflows rely on pharmacy benefit managers, third-party administrators, brokers, clearing houses, cloud providers, analytics vendors, care management suppliers, medical review firms, translation services and mailing vendors. These parties handle sensitive data, member communications, authorisation support, claims administration and purchaser distribution under contracts that can transfer both operational and conduct risk.

Why it may be material

Third-party failures can cause inaccurate member communications, delayed files, privacy leakage, claims disruption, non-compliant sales conduct and weak accessibility for members with disabilities or language needs. Vendor governance is therefore tied to member impacts, regulatory exposure, purchaser trust and resilience of critical managed care processes.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach supply-chain workers.
Potential effects may reach workers.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers, Value chain workers.
The source places the pathway in Upstream, Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may affect insurance availability, coverage terms, premiums or claims.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Supplier workforce, audit, grievance and remediation records
Workforce, health and safety, engagement and grievance records
Community engagement, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Insurance coverage, premium, exclusion and claims records
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (assets): Licences, brand reputation, government plan contracts, accreditation status and broker distribution relationships
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Suppliers
Value chain workers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS Business conduct and management of relationships with suppliers; consumers and end-users where outsourced services affect memberssearch disclosure cards
GRI Supplier assessment, procurement practices and customer impacts through outsourced servicessearch disclosure cards
SASB third-party administration, data security, legal proceedings and plan performance where vendors are involved

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Medicine traceability and anti-counterfeiting controls covers governance and operational checks that verify legitimate medicines, manage recalls and returns, prevent diversion and keep falsified, expired or tampered products out of pharmacy stock and patient supply.

How it shows up in this industry

Drug retailers receive medicines from manufacturers and full-line wholesalers into branches, distribution centres, stock rooms and central-fill hubs. Serialisation scanners, barcode controls, cold-chain verification, returns quarantine and recall workflows are required to prevent counterfeit, expired, diverted or tampered medicines from reaching patients.

Why it may be material

Traceability failures can cause treatment failure, toxicity, recall costs, stock losses, regulatory enforcement and loss of wholesaler, manufacturer or payer confidence. Moves towards interoperable electronic prescriptions and medicine verification make system investment and execution financially material.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Potential effects may reach supply-chain workers.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers.
The source places the pathway in Upstream, Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Supplier workforce, audit, grievance and remediation records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Central-fill dispensing hubs using automated picking, verification and pouch-packing equipment
Process-map item (assets): Delivery vans, courier contracts and last-mile delivery infrastructure for home medicines supply
Process-map item (assets): Robotic dispensing units, barcode verification systems, electronic prescription service connections and serialisation scanners
Process-map item (customers): Patients requiring specialist handling for high-cost biologics, cold-chain medicines or controlled drugs
Process-map item (emerging_pressures): Expansion of online-only pharmacies, telehealth prescribing and direct-to-consumer medicine delivery, increasing pressure on branch economics and verification controls

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 supplier relationship controlssearch disclosure cards
ESRS ESRS S4 consumer safety impactssearch disclosure cards
GRI GRI customer health and safety and supplier assessment disclosures where applicablesearch disclosure cards
SASB SASB Drug Retailers counterfeit drugs, medicine traceability, inventory integrity and recall controls

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Patient data privacy and pharmacy cybersecurity covers governance, controls and resilience for sensitive health, prescription, payer, payment and loyalty data used in branches, central-fill hubs, mobile ordering, electronic prescription services and claims networks.

How it shows up in this industry

Drug retailers hold patient medication records, prescription histories, diagnosis-related information, payer adjudication data, payment details and loyalty data across branch systems, e-commerce platforms, mobile ordering, electronic prescription services and pharmacy benefit manager interfaces. Ransomware or unauthorised disclosure can halt dispensing and expose sensitive health information at scale.

Why it may be material

Privacy and cybersecurity affect regulatory penalties, breach response costs, cyber-insurance terms, digital pharmacy growth, payer interfaces and brand trust. Digital prescription flows, mobile ordering and cloud-hosted pharmacy systems increase attack surfaces and make system downtime material for patients and revenue.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Potential effects may reach workers.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Patient medication records, prescription histories, loyalty data and payer adjudication data sets
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Robotic dispensing units, barcode verification systems, electronic prescription service connections and serialisation scanners

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 consumers and end-users: privacysearch disclosure cards
ESRS ESRS G1 governance controls where cyber governance is materialsearch disclosure cards
GRI GRI customer privacy disclosuressearch disclosure cards
SASB SASB Drug Retailers data security, privacy and electronic health information protection

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Digital and physical controls that keep counterfeit, falsified, stolen, expired, recalled or damaged products out of legitimate health care distribution channels.

How it shows up in this industry

Warehouse management, enterprise resource planning, serialisation and track-and-trace platforms support receipt, quarantine release, automated picking, batch and serial number capture, electronic proof of delivery and recall execution for prescription medicines, medical devices, diagnostics and secondary wholesale flows. Requirements under the US Drug Supply Chain Security Act and the EU Falsified Medicines Directive make verification central to wholesale distribution.

Why it may be material

Failure to verify product identity or execute recalls can allow falsified, stolen, expired, recalled or damaged products to reach patients, causing enforcement, product liability and loss of manufacturer mandates. Expansion of interoperable verification increases systems CAPEX and operating controls.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Specialty pharmaceutical hubs for biologics, cell and gene therapy kits, vaccines and oncology products
Process-map item (assets): Warehouse management, enterprise resource planning, serialisation and track-and-trace platforms
Process-map item (assets): Reverse-logistics facilities for returns, recalls, expired medicines and damaged stock
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Business partners
Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-users; product safety and information integritysearch disclosure cards
GRI GRI 416 Customer Health and Safetysearch disclosure cards
SASB SASB Health Care Distributors; counterfeit drugs and drug supply-chain integrity

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The governance and public-interest impact of accurate government plan data, compliant risk adjustment and effective fraud, waste and abuse controls.

How it shows up in this industry

Government-sponsored managed care revenue depends on capitation, risk adjustment, quality bonus payments, encounter data and compliance reporting to public purchasers. Actuarial models, risk-scoring models, claims histories, pharmacy data, provider coding incentives and special investigation units support pricing, risk transfers and fraud, waste and abuse controls in Medicare Advantage, Medicare Part D and Medicaid managed care.

Why it may be material

Coding integrity and encounter data quality directly affect premium revenue, government capitation payments, risk-adjustment transfers and public expenditure. Tighter audits and enforcement can create material recoveries, penalties, contract sanctions and exclusion from government programmes, while weak controls undermine confidence in publicly funded managed care.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Claims adjudication platforms, eligibility engines and electronic data interchange gateways connected to hospitals, clinics, laboratories and pharmacies
Process-map item (assets): Actuarial models, risk-scoring models, utilisation management rules, formularies and clinical policy libraries
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (assets): Office space, regional service centres and hybrid-working infrastructure for claims, clinical review, sales and compliance staff
Process-map item (assets): Licences, brand reputation, government plan contracts, accreditation status and broker distribution relationships

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
Regulators

Standards to check

ESRS Business conduct, corruption and compliance management, including public-sector contracting integritysearch disclosure cards
GRI Anti-corruption, public policy, compliance and economic impactssearch disclosure cards
SASB fraud, waste and abuse; regulatory compliance; plan performance

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance of critical supplier resilience, procurement controls and due diligence for clinical inputs and outsourced services that determine safe, continuous and responsible care delivery.

How it shows up in this industry

Health care delivery relies on just-in-time deliveries of sterile consumables, implants, medicines, reagents, vaccines, biologics, blood products, medical gases, oxygen, contrast media, linen, food, electronic components and equipment maintenance through distributors, group purchasing networks and outsourced service providers. Shortages or poor supplier quality can cancel diagnostics, surgery, critical care, dialysis and laboratory services.

Why it may be material

Supply disruption can cancel operations, delay diagnostics, restrict intensive care or dialysis and increase spot purchasing costs. Providers also face pressure to evidence responsible, low-carbon and resilient procurement claims for gloves, gowns, devices, food, linen, electronics and pharmaceuticals without compromising patient safety.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach supply-chain workers.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees, Suppliers.
The source places the pathway in Upstream, Own operations, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What geopolitical developments could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Supplier workforce, audit, grievance and remediation records
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Sterilisation units, pharmacies, blood banks, medical gas manifolds and bulk oxygen tanks
Process-map item (assets): Building services infrastructure including HVAC, boilers, chillers, backup generators, uninterrupted power supply systems and water treatment plant
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots
Process-map item (assets): Digital assets including electronic health records, clinical decision support systems, patient portals, telehealth platforms, scheduling systems and cyber-security controls
Process-map item (assets): Clinical licences, accreditation status, payer contracts, provider networks, care pathways, clinical protocols and patient trust as intangible assets

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant upstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Business partners
Customers / end-users
Employees
Suppliers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 Business conduct for supplier relationship managementsearch disclosure cards
ESRS ESRS S2 Value chain workerssearch disclosure cards
ESRS ESRS E5 Resource use may apply where materialsearch disclosure cards
GRI GRI 204 Procurement Practicessearch disclosure cards
GRI GRI 308 Supplier Environmental Assessmentsearch disclosure cards
GRI GRI 414 Supplier Social Assessmentsearch disclosure cards
SASB SASB Health Care Delivery does not provide a simple one-to-one anchor; operational continuity and quality topics may partially apply

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance and transparency of public policy engagement by health care distributors where advocacy can shape rules for medicine access, controlled substances, traceability, procurement, packaging, transport and data governance.

How it shows up in this industry

Health care distributors have interests in wholesale distribution rules, controlled-substance monitoring expectations, drug supply-chain security, medicine shortage reporting, public procurement, reimbursement, cold-chain packaging restrictions, transport rules and data protection. Policy engagement can influence rules that shape patient access, public health safeguards and distribution economics.

Why it may be material

Advocacy that appears to weaken opioid monitoring, shortage transparency, product traceability or environmental controls can damage trust and attract scrutiny from public buyers, investors and civil society. Transparent governance helps demonstrate that policy positions support safe, resilient and lawful medicine distribution.

Impact pathway

Potential effects may reach affected communities.
Potential effects may reach consumers.
Potential effects may reach downstream users.
Affected stakeholder groups identified in the source include Customers / end-users.
The source places the pathway in Own operations, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may affect access to finance, funding terms or the cost of capital.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Community engagement, grievance and impact records
Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Revenue, demand, pricing and market-access analysis linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Funding terms, lender or investor requirements and cost-of-capital analysis
Process-map item (assets): Regional pharmaceutical distribution centres with ambient, chilled and frozen storage zones
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications
Process-map item (customers): Government stockpiles, public health agencies and emergency preparedness bodies
Process-map item (emerging_pressures): Pressure for medicine access, shortage transparency and fair allocation during supply disruptions
Process-map item (external_impacts): Traffic congestion, noise, idling emissions and road safety risks around distribution depots and hospital delivery bays

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.

Affected stakeholders

Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS G1 Business conduct; political engagement and lobbying activitiessearch disclosure cards
GRI GRI 415 Public Policysearch disclosure cards
GRI GRI 2 governance disclosuressearch disclosure cards
SASB SASB Health Care Distributors does not clearly isolate lobbying as a sector topic

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

The governance of lobbying, political spending and trade association activity where managed care organisations seek to influence healthcare, insurance and pharmacy benefit regulation.

How it shows up in this industry

Managed care organisations are directly affected by federal and state rules on essential health benefits, medical loss ratios, risk adjustment, Medicare Advantage, Medicare Part D, Medicaid managed care, network adequacy, mental health parity, interoperability, price transparency and pharmacy benefit management. Public policy engagement can influence rules that determine member access, premiums, public budgets and provider relationships.

Why it may be material

Policy engagement is financially material where regulation shapes plan design, capitation, risk adjustment, rebates, utilisation management and market access. It is also an accountability issue where lobbying positions conflict with stated commitments on affordability, health equity, parity or transparent member information.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may affect access to finance, funding terms or the cost of capital.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Funding terms, lender or investor requirements and cost-of-capital analysis
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Actuarial models, risk-scoring models, utilisation management rules, formularies and clinical policy libraries
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants
Process-map item (customers): Individual members buying exchange, marketplace or direct health insurance products

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS Business conduct: political engagement, lobbying activities and relationships with public authoritiessearch disclosure cards
GRI Public policy and political contributionssearch disclosure cards
SASB regulatory environment and legal proceedings, subject to sector-specific confirmation

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance of public policy engagement and political activity in a heavily regulated care delivery environment.

How it shows up in this industry

Health care delivery is shaped by public payer tariffs, diagnosis-related groups, capitation, value-based payment models, facility licensing, accreditation, professional scope-of-practice rules, controlled drug laws, data protection requirements, public health duties and planning decisions for hospitals and clinics. Providers and their trade associations may engage with governments on reimbursement levels, inspection regimes, staffing policy, access requirements, digital health rules and estate approvals.

Why it may be material

Policy engagement can materially influence revenue models, service eligibility, workforce flexibility, patient access, inspection expectations and public trust. Misaligned or opaque advocacy can damage credibility where providers publicly commit to health equity, patient safety, decarbonisation or affordability while lobbying against supporting regulation.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach workers.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Workforce, health and safety, engagement and grievance records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Provision, claim, penalty, remediation and contingent-liability records
Process-map item (assets): Clinical licences, accreditation status, payer contracts, provider networks, care pathways, clinical protocols and patient trust as intangible assets
Process-map item (customers): Public payers such as national health services, Medicare and Medicaid-type schemes, social insurance funds and local authorities
Process-map item (customers): Pharmaceutical and medical technology companies using provider sites for clinical trials and real-world evidence studies
Process-map item (emerging_pressures): Antimicrobial resistance increasing infection control costs, stewardship requirements and risks from healthcare-associated infections
Process-map item (external_impacts): Healthcare risk waste, sharps, pharmaceutical residues, cytotoxic waste and infectious materials requiring incineration, autoclaving or specialist treatment

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS G1 Business conduct: political influence and lobbying activitiessearch disclosure cards
GRI GRI 415 Public Policysearch disclosure cards
SASB SASB Health Care Delivery has no simple public policy engagement topic; issue may be entity-specific

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Public policy engagement in pharmacy covers transparent and accountable lobbying, trade association activity and political engagement on the rules governing reimbursement, pharmacy access, controlled drugs, online prescribing, data sharing, medicine take-back and public health service delivery.

How it shows up in this industry

Drug retailers are affected by public reimbursement rates, dispensing fees, pharmacy benefit manager terms, national pharmacy service specifications, controlled-drug regulation, medicine take-back schemes, data-sharing rules and policies on online prescribing. Chains may engage with governments, regulators, trade associations and health systems on rules that shape access to medicines, branch economics and service models.

Why it may be material

Policy engagement can influence reimbursement, branch closures, service availability, controlled-drug safeguards and digital pharmacy rules. Poorly governed lobbying can create reputational damage, investor concern and mistrust if corporate positions appear misaligned with medicine access, patient safety or public health objectives.

Impact pathway

Potential effects may reach affected communities.
Potential effects may reach consumers.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Community engagement, grievance and impact records
Consumer outcome, complaint and product-impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Brand reputation, pharmacy licences, payer network contracts and supplier trading agreements
Process-map item (customers): Walk-in retail customers buying prescription medicines, over-the-counter medicines, health and beauty products and medical devices

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS G1 political influence and lobbying activitiessearch disclosure cards
GRI GRI public policy disclosuressearch disclosure cards
SASB SASB Drug Retailers business model and regulatory environment topics where public policy affects access, reimbursement and controlled substances

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Supplier and third-party due diligence for pharmacy networks covers governance of critical business partners that support medicine sourcing, delivery, waste management, technology, claims processing and outsourced services, including labour, sanctions, continuity, conduct and compliance checks.

How it shows up in this industry

Drug retailers rely on full-line pharmaceutical wholesalers, medicine manufacturers, health and beauty suppliers, third-party logistics, couriers, waste contractors, cloud hosting, payment processors, claims adjudication services, call centres, cleaning and security contractors. These relationships affect medicine availability, labour conditions, privacy, waste handling, delivery safety and continuity of pharmacy services.

Why it may be material

Complex third-party networks create regulatory, operational and reputational exposure beyond direct branch operations. Weak due diligence can lead to service disruption, waste contractor breaches, labour-rights concerns, poor courier conduct, supplier sanctions exposure, privacy weaknesses or loss of payer and customer confidence.

Impact pathway

Potential effects may reach supply-chain workers.
Potential effects may reach contractors.
Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach water bodies.
Potential effects may reach ecosystems.
Affected stakeholder groups identified in the source include Business partners, Contractors, Customers / end-users, Suppliers, Value chain workers.
The source places the pathway in Upstream, Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Supplier workforce, audit, grievance and remediation records
Contractor working-condition, incident and engagement records
Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Water withdrawal, discharge, quality and catchment-impact records
Biodiversity, habitat and ecosystem-impact evidence
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Delivery vans, courier contracts and last-mile delivery infrastructure for home medicines supply
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations
Process-map item (assets): Brand reputation, pharmacy licences, payer network contracts and supplier trading agreements

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Business partners
Contractors
Customers / end-users
Suppliers
Value chain workers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 supplier relationship managementsearch disclosure cards
ESRS ESRS S2 workers in the value chain where labour impacts are materialsearch disclosure cards
GRI GRI supplier assessment, procurement practices and modern slavery-related disclosures where applicablesearch disclosure cards
SASB SASB Drug Retailers supply chain management, distribution integrity and business partner controls where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance of third-party relationships that underpin regulated medicine distribution, including supplier qualification, licence verification, labour-rights due diligence, contractor audits and assurance over outsourced logistics, destruction, packaging and digital services.

How it shows up in this industry

Distributors depend on licensed medicine and device manufacturers, secondary wholesalers, specialist cold-chain carriers, secure controlled-substance couriers, hazardous waste destruction contractors, packaging suppliers, cloud hosting providers, serialisation platforms and temporary labour agencies. Supplier failures can introduce falsified products, unsafe working conditions, data compromise, poor destruction records or service disruption.

Why it may be material

Complex third-party networks are essential to inbound freight, temperature-controlled lanes, secure transport, reverse logistics, IT systems and agency labour. Public buyers increasingly request modern slavery due diligence, resilient supply plans and assurance over critical suppliers, while supplier failures can trigger liability and loss of customer confidence.

Impact pathway

Potential effects may reach supply-chain workers.
Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers, Value chain workers.
The source places the pathway in Upstream, Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Supplier workforce, audit, grievance and remediation records
Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Licences, manufacturer distribution agreements, payer and group purchasing organisation contracts, and Good Distribution Practice certifications
Process-map item (emerging_pressures): Growth in biologics, GLP-1 medicines, vaccines and cell therapies increasing demand for validated cold-chain capacity
Process-map item (emerging_pressures): Customer and investor pressure to cut diesel fleet emissions, refrigerant leakage and single-use cold-packaging waste
Process-map item (emerging_pressures): Pressure for medicine access, shortage transparency and fair allocation during supply disruptions
Process-map item (emerging_pressures): Restrictions on PFAS, PVC, expanded polystyrene and other materials used in medical and cold-chain packaging

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Suppliers
Value chain workers

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 Business conductsearch disclosure cards
ESRS ESRS S2 Workers in the value chain and supply-chain due diligence aspectssearch disclosure cards
GRI GRI 308 Supplier Environmental Assessmentsearch disclosure cards
GRI GRI 414 Supplier Social Assessmentsearch disclosure cards
GRI GRI 2 due diligence disclosuressearch disclosure cards
SASB SASB Health Care Distributors; supply-chain integrity and supplier management aspects

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Emerging issue
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Accountability for the safety, fairness, transparency, validation and monitoring of AI-enabled clinical and operational decision tools used in care delivery.

How it shows up in this industry

Providers increasingly deploy artificial intelligence in diagnostic imaging centres, pathology workflows, patient scheduling, clinical documentation and decision support systems connected to electronic health records. These tools influence diagnosis, waiting-list prioritisation, escalation of deteriorating patients, clinician workload and documentation integrity.

Why it may be material

AI tools can affect diagnosis quality, waiting-list prioritisation, documentation integrity and clinician workload. Regulatory scrutiny and litigation over algorithmic bias and unsafe deployment are increasing, requiring governance that connects clinical safety, data protection, procurement, credentialling and incident review.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach workers.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Customers / end-users, Employees.
The source places the pathway in Own operations, Upstream, Downstream.

Financial pathway

The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect demand, pricing, market access or product and service revenue.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may affect insurance availability, coverage terms, premiums or claims.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Workforce, health and safety, engagement and grievance records
Community engagement, grievance and impact records
Provision, claim, penalty, remediation and contingent-liability records
Revenue, demand, pricing and market-access analysis linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Insurance coverage, premium, exclusion and claims records
Process-map item (assets): Acute hospitals with operating theatres, emergency departments, intensive care units, wards, maternity units and isolation rooms
Process-map item (assets): Outpatient clinics, diagnostic imaging centres, ambulatory surgery centres and rehabilitation facilities
Process-map item (assets): Laboratories for pathology, microbiology, blood testing and point-of-care diagnostics
Process-map item (assets): Sterilisation units, pharmacies, blood banks, medical gas manifolds and bulk oxygen tanks
Process-map item (assets): Clinical equipment such as MRI and CT scanners, linear accelerators, endoscopes, infusion pumps, ventilators, dialysis machines and surgical robots

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
NGOs / civil society
Regulators

Standards to check

ESRS ESRS G1 Business conductsearch disclosure cards
ESRS ESRS S4 Consumers and end-users for consumer impacts and digital governancesearch disclosure cards
GRI GRI 416 Customer Health and Safety orsearch disclosure cards
GRI GRI 418 Customer Privacy may be partial proxiessearch disclosure cards
SASB quality of care and patient privacy may be relevant by interpretation

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Emerging issue
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Digital pharmacy verification accountability covers governance of AI-enabled and automated pharmacy workflows, including e-prescription validation, telehealth-originated prescription checks, clinical decision support, pharmacist overrides, automated pouch-packing and central-fill verification.

How it shows up in this industry

Drug retailers increasingly receive prescriptions from electronic prescription services, telehealth platforms and repeat-prescription systems, then process them through central-fill automation, robotic picking, barcode verification, pouch-packing and clinical decision support. Online-only pharmacies and AI-enabled triage make accountability for automated checks, pharmacist overrides, exception handling and false assurance a material governance challenge.

Why it may be material

Digital prescription inflows and automated fulfilment can reduce workload and improve consistency, but poor configuration, weak change control or unclear pharmacist accountability can replicate the same verification failure across many branches, central-fill hubs or delivery patients. The topic is especially material where pharmacies use remote clinical checks, direct-to-consumer medicine supply, automated pouch-packing or telehealth-originated prescription intake.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach workers.
Potential effects may reach downstream users.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What is the scale, scope, likelihood and remediability of effects on workers?
What technology changes could alter the topic's impacts or financial effects?

Evidence to collect

Consumer outcome, complaint and product-impact records
Workforce, health and safety, engagement and grievance records
Downstream-user outcome, complaint and product-use evidence
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): High-street and supermarket pharmacy branches with dispensaries, consultation rooms and secured medicines cabinets
Process-map item (assets): Central-fill dispensing hubs using automated picking, verification and pouch-packing equipment
Process-map item (assets): E-commerce, repeat-prescription and mobile ordering platforms linked to pharmacy management systems
Process-map item (assets): Patient medication records, prescription histories, loyalty data and payer adjudication data sets
Process-map item (assets): Pharmacist, pharmacy technician and healthcare adviser workforce, including professional registrations and controlled-drug authorisations

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 consumers and end-users: product safety impacts from digitalised service deliverysearch disclosure cards
GRI GRI customer health and safety and product responsibility disclosuressearch disclosure cards
SASB SASB Drug Retailers patient health and safety or business model resilience metrics, if applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Emerging issue
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance of competition, conflicts of interest and fair dealing where managed care entities integrate insurance, pharmacy benefit management, care delivery, data platforms and provider contracting.

How it shows up in this industry

Managed care organisations increasingly combine insurance, pharmacy benefit management, speciality pharmacy, clinics, analytics vendors and provider groups. Antitrust and competition scrutiny is rising where vertical integration may influence formularies, network inclusion, referral pathways, reimbursement, data access and member steering toward affiliated services.

Why it may be material

Competition governance is increasingly material because market structure can affect member choice, provider bargaining power, medicine affordability and public programme expenditure. The issue is particularly material for diversified health plans with pharmacy benefit managers, provider assets or data platforms.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.
The topic may affect access to finance, funding terms or the cost of capital.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Community engagement, grievance and impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Funding terms, lender or investor requirements and cost-of-capital analysis
Process-map item (assets): Member portals, mobile applications, nurse advice lines, contact centres and secure messaging channels used for enrolment, complaints and care navigation
Process-map item (assets): Provider network contracts, credentialling files, fee schedules, capitation arrangements and value-based care agreements
Process-map item (assets): Data warehouses containing claims histories, encounter data, pharmacy data, prior authorisation records, quality measures and demographic data
Process-map item (customers): Employer groups purchasing insured or administrative-services-only health benefit plans for employees and dependants
Process-map item (customers): Medicare Advantage, Medicare Part D and Medicaid managed care beneficiaries enrolled through government-sponsored plans

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Business partners
Customers / end-users
Suppliers

Users of the information

Investors / creditors
Regulators

Standards to check

ESRS Business conduct, anti-competitive behaviour and responsible business relationshipssearch disclosure cards
GRI GRI 206 Anti-competitive Behaviorsearch disclosure cards
SASB Managed Care may indirectly capture customer welfare and regulatory issues but not vertical integration as a standalone topic

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Which topics should you investigate first?

Initial screening

Start here

Check if applicable

Emerging issues

Candidate topics — Healthcare Providers, Services and Technology

Clinical waste, sharps and hazardous healthcare materials Health Care Delivery Matched to profile Start here Strong signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Hospital energy, medical gas and carbon transition Health Care Delivery Matched to profile Start here Strong signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Low-carbon logistics and refrigerant management Health Care Distributors Matched to profile Start here Strong signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Medicine take-back and end-of-life stewardship Drug Retailers Matched to profile Start here Strong signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Pharmaceutical returns and hazardous waste destruction Health Care Distributors Matched to profile Start here Strong signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Physical climate resilience of medicine distribution networks Health Care Distributors Matched to profile Start here Moderate signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Clinical, sharps and retail packaging waste Drug Retailers Matched to profile Check if applicable Moderate signal

What this topic covers